Introduction {#sec1-0300060519845491}
============

Gastric cancer (GC) is the second most common cause of cancer-related deaths worldwide, with almost 50% of all cases occurring in China.^[@bibr1-0300060519845491]^ Most patients are already at an advanced stage when a diagnosis of GC is made.^[@bibr2-0300060519845491],[@bibr3-0300060519845491]^ Although surgical resection is the main treatment for localized/regional GC, many patients with advanced GC fail to achieve satisfactory R0 resection rates after surgery alone. Two previous studies reported unsatisfactory postoperative survival rates of patients with stage III GC, but adjuvant chemotherapy with S-1^[@bibr4-0300060519845491]^ or capecitabine/oxaliplatin after D2 gastrectomy improved the survival of patients with stage II/III GC.^[@bibr5-0300060519845491]^ Compared with adjuvant chemotherapy, preoperative or neoadjuvant chemotherapy (NAC) is a promising approach that has been shown to improve the R0 resection rate, the response to intensive regimens, and the rate of chemotherapy initiation, while reducing chemotherapy toxicities and unnecessary surgery.^[@bibr6-0300060519845491]^ Among many randomized, controlled trials, the MAGIC and FNCLCC/FFCD trials showed that NAC improved progression-free survival and overall survival (OS) rates compared with surgery alone.^[@bibr7-0300060519845491],[@bibr8-0300060519845491]^ Although advances in treatments and understanding of GC have improved chemotherapy response rates to ≥50%,^[@bibr7-0300060519845491],[@bibr9-0300060519845491]^ this remains unsatisfactory, and further research thus aims to identify more accurate and effective methods for improving patient survival. However, given that the same treatment regimen cannot be applied to everyone, extensive attention has been focused on individualized treatments, including the identification of markers for screening out patients likely to benefit from chemotherapy.

In the current study, we examined the association between tumor blood supply and response to NAC in patients with advanced GC, and also analyzed its relationships with OS and clinicopathologic characteristics.

Patients and methods {#sec2-0300060519845491}
====================

Patients {#sec3-0300060519845491}
--------

This retrospective study included 53 patients with advanced GC (stage III, Bormann type II and III) who underwent preoperative intra-arterial and intravenous infusion chemotherapy at Changzhou No. 2 People's Hospital, Affiliated Hospital of Nanjing Medical University, Changzhou, China, from January 2010 to August 2013. All patients were diagnosed with GC by gastroscopic biopsy and were evaluated by contrast-enhanced computed tomography (CT) scan. Patients with potential peritoneal metastases were evaluated by laparoscopy and peritoneal cytology. Preoperative staging was carried out according to the 6th edition UICC TNM classification and the number of lymph node stations was determined according to the Japanese Gastric Cancer Association (JGCA) classification.^[@bibr10-0300060519845491]^

Preoperative chemotherapy and follow-up {#sec4-0300060519845491}
---------------------------------------

Preoperative intra-arterial infusion chemotherapy was administered using Seldinger's approach via the femoral artery. The FLEEFOX chemotherapy protocol was administered as follows: 5-fluorouracil (370 mg/m^2^) and leucovorin (200 mg/m^2^) by intravenous infusion on days 1--5, and intra-arterial administration of etoposide (80 mg/m^2^), oxaliplatin (80 mg/m^2^), and epirubicin (30 mg/m^2^) via the Seldinger method on days 6 and 20, repeated for two cycles. The chemotherapeutic response was evaluated by contrast-enhanced CT scan independently by two experienced radiologists who were blinded to the clinical data, according to the criteria of the JGCA.^[@bibr10-0300060519845491]^ All patients were reappraised by CT after NAC. Patients considered to be resectable underwent gastrectomy with D2 lymphadenectomy, or D2+ lymphadenectomy if preoperative CT indicated N3 lymph node metastasis. Patients received six cycles of postoperative adjuvant chemotherapy with XELOX, involving oxaliplatin (130 mg/m^2^) on day 1 and capecitabine (1000 mg/m^2^) on days 1--14 of a 28-day cycle. Patients considered to be unresectable or who declined surgery received other regimens and/or best supportive care. The protocol was approved by the Chinese Ethics Committee of Registering Clinical Trials, and the independent Institutional Review Board and Ethics Committee of Changzhou No. 2 People's Hospital. All patients provided written informed consent.

Tumor CT values {#sec5-0300060519845491}
---------------

The CT imaging system automatically measured the CT value. We measured each tumor CT enhancement value before chemotherapy (CT1; arterial phase CT value−plain phase CT value; average of five). To eliminate individual differences, we also measured the liver parenchyma CT enhancement value (CT2) using the same method. The tumor blood supply was defined as good or poor according to the median CT1/CT2 value. This method is illustrated in Supplemental Figure 1.

Clinical response and histological evaluation of surgical specimens {#sec6-0300060519845491}
-------------------------------------------------------------------

Each patient was examined by contrast-enhanced CT scan after two cycles of preoperative chemotherapy. Tumors were staged based on the JGCA criteria^[@bibr10-0300060519845491]^ ([Tables 1](#table1-0300060519845491){ref-type="table"} and [2](#table2-0300060519845491){ref-type="table"}).

###### 

Definition of clinical response in primary lesion.

![](10.1177_0300060519845491-table1)

  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Complete response (CR)     Disappearance of all tumor lesions and no diagnosis of carcinoma; biopsy specimens negative for carcinoma
  Partial response (PR)      
   a-lesions                 At least a 30% decrease in total size
   b-lesions                 Remarkable regression and flattening of tumor on X-ray/endoscopic examinations, roughly corresponding to at least 50% decrease in tumor size
   c-lesions                 At least 50% enlargement of gastric lumen in the area of the lesions by X-ray examination
  Stable disease (SD)        Changes in tumor size or shape less than PR, but not progressive disease (PD)
  Progressive disease (PD)   Increase in tumor size and/or worsening of shape (20% or more increase in a-lesions), or new intragastric lesions
  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------

CR or PR cases were considered as responders.

###### 

Histological evaluation criteria for tumor response after preoperative therapy.

![](10.1177_0300060519845491-table2)

  -------------------------------- --------------------------------------------------------------------------------------------------
  Grade 0 (no effect)              No evidence of effect
  Grade 1 (slight effect)          
   Grade 1a (very slight effect)   Viable tumor cells occupy more than 2/3 of the tumorous area
   Grade 1b (slight effect)        Viable tumor cells remain in more than 1/3 but less than 2/3 of the tumorous area
  Grade 2 (considerable effect)    Viable tumor cells remain in less than 1/3 of the tumorous area
  Grade 3 (complete response)      No viable tumor cells remain; recommended that the finding is confirmed on additional sectioning
  -------------------------------- --------------------------------------------------------------------------------------------------

Patients with grade 0--1a lesions were regarded as pathological non-responders and those with grades 1b--3 lesions were regarded as pathological responders.

Statistical analysis {#sec7-0300060519845491}
--------------------

Statistical analyses were performed using IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism version 6.0 (GraphPad Software Inc., San Diego, CA, USA). OS was calculated from the date of first NAC to the date of death or last follow-up. Comparisons between groups were analyzed by unpaired test or Fisher's exact test. Survival curves were estimated according to the Kaplan--Meier method, and differences between the curves were analyzed using the log-rank test. Hazard ratios were determined using Cox proportional hazards regression. *P* values \< 0.05 were considered to be significant.

Results {#sec8-0300060519845491}
=======

Clinical response {#sec9-0300060519845491}
-----------------

The characteristics of the 53 patients are shown in [Table 3](#table3-0300060519845491){ref-type="table"}. Thirty-six patients were responders. Three patients (5.66%) obtained a complete response (CR), including two with a good blood supply (GBS) and one with a poor blood supply (PBS). Thirty-three patients (62.26%) obtained a partial response (PR), including 18 with a GBS and 15 with a PBS. Thirteen patients (24.52%) achieved stable disease (SD), including three with a GBS and 10 with a PBS, and four patients (7.54%) achieved progressive disease (PD), including one with a GBS and three with a PBS. The overall response rate was 67.92% (36/53 cases) and the response rates in the GBS and PBS groups were 83.33% (20/24 cases) and 55.17% (16/29 cases), respectively (*P* = 0.039) ([Figure 1](#fig1-0300060519845491){ref-type="fig"}).

###### 

Patient characteristics (n=53).

![](10.1177_0300060519845491-table3)

  Characteristic                           No. patients   \%
  ---------------------------------------- -------------- ------
  Median age (range) (years) 58 (30--73)                  
  Sex                                                     
   Male                                    35             66
   Female                                  18             34
  Macroscopic type                                        
   Type 2                                  17             32.1
   Type 3                                  25             4.2
   Type 4                                  11             20.7
  Tumor location                                          
   UM                                      21             39.6
   ML/MU/MUL                               8              15.1
   LM                                      24             45.3
  Histopathology subtype                                  
   Well-differentiated  adenocarcinoma     18             33.9
   Moderately differentiated               26             49.1
   Poorly differentiated  adenocarcinoma   2              3.8
   Signet-ring cell carcinoma              7              13.2
  TNM stage                                               
   IIIB                                    32             60.4
   IIIC                                    21             39.6

Lesion location classified according to the JCGA (3nd English Edition). U, M, L: bulk of tumor located in the upper, middle, or lower third of the stomach, respectively.

![Clinical response in patients with GBS and PBS. GBS: good blood supply, PBS: poor blood supply, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.](10.1177_0300060519845491-fig1){#fig1-0300060519845491}

Pathological findings {#sec10-0300060519845491}
---------------------

The pathological findings are summarized in [Tables 4](#table4-0300060519845491){ref-type="table"}and[5](#table5-0300060519845491){ref-type="table"}. Four patients refused surgery and the tumors in another four patients could not be resected because of syncretic lymph nodes enclosing the pivotal arteries. Pathological response (grade 1b--3) was observed in 34 patients (75.55%). Eight patients (17.78%; 6 GBS, 2 PBS) obtained CR. The pathological response rates were 90.91% (20/22) and 60.87% (14/23) in patients with a GBS and PBS, respectively (*P* = 0.0351) ([Figure 2](#fig2-0300060519845491){ref-type="fig"}).

###### 

Pathological findings (n = 45).

![](10.1177_0300060519845491-table4)

  Pathological finding       No. patients (%)
  -------------------------- ------------------
  No tumor (PCR)             8 (17.78)
  pT1                        3 (6.67)
  pT2                        5 (11.11)
  pT3                        0 (0)
  pT4                        29 (64.44)
  Lymph node metastasis      
   pN0                       14 (31.11)
   pN1                       8 (17.78)
   pN2                       9 (20)
   pN3                       6 (13.33)
  Pathological tumor stage   
   IA, IB                    3 (6.67)
   IIA, IIB                  15 (33.33)
   IIIA, IIIB                19 (42.22)
   IV                        0 (0)

###### 

Pathological response to FLEEOX therapy according to blood supply.

![](10.1177_0300060519845491-table5)

        Grade 0   Grade 1a   Grade 1b   Grade 2   Grade 3
  ----- --------- ---------- ---------- --------- ---------
  GBS   1         1          11         3         6
  PBS   2         7          8          4         2

GBS: good blood supply, PBS: poor blood supply.

![Pathological response in patients with GBS and PBS. GBS: good blood supply, PBS: poor blood supply, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease.](10.1177_0300060519845491-fig2){#fig2-0300060519845491}

Relationships between blood supply and clinicopathologic characteristics {#sec11-0300060519845491}
------------------------------------------------------------------------

The relationships between blood supply and clinicopathologic characteristics are shown in [Table 6](#table6-0300060519845491){ref-type="table"}. There was no significant relationship between tumor blood supply and any clinicopathologic parameter except tumor macroscopic type (B3 vs. B2, *P* \< 0.001). We also assessed the relationship between tumor blood supply and response to chemotherapy, and showed that tumor blood supply was significantly related to both radiographic and pathological chemotherapy responses (*P* = 0.039 and *P* = 0.035, respectively).

###### 

Relationships between blood supply and clinicopathologic characteristics.

![](10.1177_0300060519845491-table6)

                         *P* value
  ---------------------- -------------
  Age (years)            
   ≥58 vs. \<58          0.595
  Sex                    
   Male vs. female       0.6
  TNM stage              
   IIIB vs. IIIC         0.732
  Tumor site             
   Upper vs. lower       0.425
  Macroscopic type       
   B2 vs. B3             **\<0.001**
  Histological subtype   
   G1 vs. G2             0.159

Median value of CT enhancement was used as a cut-off point to separate patients into high or low blood supply groups. Significant results indicated in bold.

Correlation between blood supply and OS {#sec12-0300060519845491}
---------------------------------------

Patients were followed-up for a median of 35 months (range 4 to 71 months). OS at 3 years was 65.8% for the entire cohort ([Figure 3](#fig3-0300060519845491){ref-type="fig"}). Univariate analysis identified GBS as significantly correlated with superior OS (GBS vs. PBS: 3-year OS 78.57% vs 54.44%, hazard ratio = 0.3773, 95% confidence interval 0.1614--0.8823, *P* = 0.0245) ([Figure 4](#fig4-0300060519845491){ref-type="fig"}).

![Overall survival in the entire cohort.](10.1177_0300060519845491-fig3){#fig3-0300060519845491}

![Kaplan--Meier survival curves showing significantly higher overall survival in patients with good blood supply compared with poor blood supply.](10.1177_0300060519845491-fig4){#fig4-0300060519845491}

Discussion {#sec13-0300060519845491}
==========

Preoperative chemotherapy, or NAC, was first proposed in the 1980s and has since become an essential adjuvant chemotherapy for patients with advanced GC.^[@bibr11-0300060519845491]^ Preoperative chemotherapy is known to play an important role in the treatment of GC by decreasing tumor cell activity and tumor volume, reducing iatrogenic tumor cell diffusion during surgery, and by improving the R0 resection rate. However, the optimal way of administering the drugs remains controversial. Local intra-arterial administration of chemotherapeutic agents was reported to produce 10-fold higher tumor serum concentrations than systemic intravenous chemotherapy; however, this route had weaker efficiency in metastatic tissues compared with the systemic intravenous route.^[@bibr12-0300060519845491]^ Kosaka et al.^[@bibr13-0300060519845491]^ compared the therapeutic efficacies of intra-arterial infusion and systemic intravenous chemotherapy in patients with advanced GC and found that the intra-arterial route was associated with a higher overall chemotherapy response rate than the systemic intravenous route. Intra-arterial infusion chemotherapy was also shown to improve the overall chemotherapy response rate of gastric carcinomas, possibly by promoting apoptosis of cancer cells and by pathological tumor necrosis, thus restraining tumor cell proliferation.^[@bibr14-0300060519845491]^

Various studies have indicated that the partial response rate (PRR) could significantly affect survival in GC patients treated with NAC, implying that PRR was a suitable endpoint in patients with advanced GC treated with NAC.^[@bibr15-0300060519845491][@bibr16-0300060519845491][@bibr17-0300060519845491][@bibr18-0300060519845491]--[@bibr19-0300060519845491]^ Patients with a high pathological response had better survival rates than those with a low pathological response.^[@bibr15-0300060519845491]^ These results suggest that increasing the PRR could improve survival among patients with advanced GC. Although several studies reported mean PRRs of NAC of 14.5% to 51% based on the same Japanese criteria used in our previous study,^[@bibr16-0300060519845491][@bibr17-0300060519845491][@bibr18-0300060519845491]--[@bibr19-0300060519845491]^ this remained unsatisfactory. However, recent studies showed greatly improved PRRs of NAC as high as 70% to 72%,^[@bibr20-0300060519845491],[@bibr21-0300060519845491]^ while the current study demonstrated even higher PRRs of 83.33% by radiography and 90.91% by pathology for patients with advanced GC with a GBS. Furthermore, to the best of our knowledge, information on the relationship between tumor blood supply and response to chemotherapy and OS in patients with advanced GC is lacking. The current results indicated significant associations between GC blood supply and both radiographic and pathological responses to chemotherapy (GBS vs. PBS, 83.33% vs 55.17% and 90.91% vs 60.87%, respectively) and OS (GBS vs. PBS, 3-year OS 78.57% vs 54.44%). Furthermore, a PRR \>80% and 3-year OS of 78.57% support the application of blood supply values in decisions regarding individualized treatment plans for patients with GC.

Borrmann developed a classification system for GC in 1926, which has since been used to describe the endoscopic and gross findings of GC. Borrmann IV GCs, including linitis plastica, are characterized by poorly differentiated tumor cells with diffusely infiltrative involvement of the stomach.^[@bibr22-0300060519845491][@bibr23-0300060519845491][@bibr24-0300060519845491]--[@bibr25-0300060519845491]^ Although the diagnosis and treatment of GC have been greatly improved, most early stage Borrmann IV GCs remain undetected and their prognosis is thus still very poor.^[@bibr26-0300060519845491],[@bibr27-0300060519845491]^ The 5-year survival rate after gastrectomy for Borrmann IV GCs is 0% to 17%, while rates for other types can reach 35% to 70%.^[@bibr28-0300060519845491][@bibr29-0300060519845491][@bibr30-0300060519845491]--[@bibr31-0300060519845491]^ The poor prognosis of Borrmann type IV GCs is associated with their characteristic biological behavior, including poorly differentiated and undifferentiated tumor cells resulting in early lymph node and adjacent organ metastases.^[@bibr32-0300060519845491]^ Borrmann IV GCs are therefore generally considered as a special type and are usually studied separately, and were thus not included in the current study.

This study was limited by the relatively small number of samples, and further large-scale, multicenter studies are needed to confirm the results.

There is currently a need for individualized and accurate treatment of patients with advanced GC, and identifying potential subgroups of patients who might benefit from a chemotherapy regimen is therefore vital. The results of the current study suggested that neoadjuvant intra-arterial and intravenous chemotherapy was more effective in patients with a GBS. Tumor blood supply may thus be a useful marker for predicting the response of patients to NAC, thus allowing intra-arterial and intravenous chemotherapy to be applied more precisely.

Supplemental Material
=====================

###### Supplemental Figure1 - Supplemental material for Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer

###### 

Click here for additional data file.
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